Internal Medicine Alert – April 15, 2006
April 15, 2006
View Issues
-
Pharmacology Watch
It has been a tough few months for marketers of vitamins and herbal products. Calcium plus vitamin D, saw palmetto, and glucosamine/chondroitin have all been the subject of studies that have questioned their efficacy. -
What is the Risk for Coronary Heart Disease in a Type 2 Diabetic Without Other Risk Factors?
There is a wide variation in the rate of coronary heart disease (CHD) in diabetes, depending on the population and existing risk factors. -
Warfarin: Blood-Thinner and Bone-Thinner?
Long-term use of warfarin is associated with an increase in osteoporotic fractures. -
Stroke vs Stroke Mimics: Diagnosis at the Bedside
The availability of a growing number of therapeutic options for acute stroke patients makes rapid and reliable diagnosis of stroke at the bedside more important than ever. -
Ranolazine Extended-Release Tablets (RanexaTM)
The fda has approved a new drug with a unique mechanism of action for the treatment of chronic angina. Ranolazine reduces the frequency of chest pains by reducing the demand for oxygen but does not have significant effect on heart rate or blood pressure. -
Clinical Briefs By Louis Kuritzky, MD
Noninferiority trials are usually designed to show that product B, which entered the therapeutic arena after product A, does not fall below a prespecified margin of efficacy compared to product A, ... -
A Not Completely Normal ECG
A picture of a 12-lead ECG was obtained from a healthy 32 year old man who had some atypical chest pain. Although there are no ECG findings suggestive of acute ischemia, doctors disagree with the computer interpretation ...